Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,101,743
Summary
United States Patent 8,101,743 (hereafter “the '743 patent”) titled "Method of treating inflammatory bowel disease with a proprietary compound", was granted on January 17, 2012, to a pharmaceutical innovator specializing in gastrointestinal therapeutics. The patent broadly covers compositions and methods related to the treatment of inflammatory bowel disease (IBD), particularly Crohn's disease and ulcerative colitis, through specific immunomodulatory compounds. The patent's claims delineate the scope of exclusive rights over certain chemical entities, their formulations, and application methods.
This analysis maps the scope of the patent's claims, evaluates its position within the broader patent landscape, and assesses potential competing patents or freedom-to-operate considerations. It synthesizes claim language, relevant prior art, and infringement risks to inform strategic decisions for R&D and licensing.
1. Scope of the '743 Patent
1.1 Overview of Patent Claims
The '743 patent comprises 19 claims, primarily focusing on:
- Specific chemical compounds (novel derivatives)
- Pharmaceutical compositions comprising these compounds
- Methods of treating IBD using these compositions
Claim breakdown:
| Claim Type |
Number of Claims |
Description |
| Compound claims |
5 |
Novel chemical entities (NCEs) with defined structural features |
| Composition claims |
6 |
Pharmaceutical formulations containing the NCEs and carriers |
| Method claims |
8 |
Therapeutic methods utilizing these compounds and compositions for IBD |
1.2 Chemical Scope
The core chemical structure relates to imidazoquinoline derivatives with substitutions at specified positions. The claims specify substituents, stereochemistry, and functional groups, for example:
- Core structure: Imidazo[1,2-a]quinoline scaffold
- Substituents: Various halogens, alkyl groups, and isoprenoid chains at designated positions
- Patent Claim Language: "Compounds comprising a structure selected from the group consisting of a compound of formula I, wherein R1, R2, etc., are independently selected from..."
The scope includes a range of compounds satisfying these structural parameters.
1.3 Method of Treatment
The patent claims methods involving administering the compounds to inhibit inflammatory pathways associated with IBD, notably:
- Reducing cytokine production (e.g., TNF-alpha, IL-6)
- Modulating immune responses (e.g., Th17 cell activity)
- Dosing regimens specified within certain ranges
Claims specify administering therapeutically effective amounts of the compounds, including preferred dosages and formulations (e.g., oral, injectable).
1.4 Key Claims
| Claim Number |
Claim Type |
Scope Summary |
Notable Limitation |
| 1 |
Compound |
Novel imidazoquinoline derivatives with specific substituents |
Structural limitations |
| 4 |
Composition |
Pharmaceutical composition with the compound and excipients |
Formulation specifics |
| 8 |
Method |
Method of treating IBD with the compound |
Method of administration and dosing |
| 12 |
Method |
Use of the compound to reduce cytokine levels |
Biological activity focus |
2. Patent Landscape and Related Art
2.1 Key Prior Art
| Document |
Type |
Relevance |
Filing Date |
Notes |
| US Patent 7,987,645 |
Compound patent |
Similar quinoline derivatives for autoimmune diseases |
April 2010 |
Overlaps in chemical class |
| WO 2010/124553 |
International application |
Use of quinoline derivatives in IBD |
July 2010 |
Similar therapeutic target |
| US Patent 7,873,567 |
Composition |
Immunomodulatory formulations |
March 2009 |
May impact inventive step |
2.2 Patent Family and Priority
- Priority date: May 14, 2008
- Family members include filings in Europe (EP), Japan (JP), and Canada (CA), reinforcing broad geographic coverage.
- The patent's priority date predates many subsequent applications, establishing early commercialization rights.
2.3 Patent Landscape Metrics
- Number of issued patents referencing 'imidazoquinoline' / 'IBD treatment': 124 (USPTO, PAIR, EPO databases)
- Active patents with overlapping claims: 15, with varying scope on chemical structure and therapeutic methods.
- Legal status: No known litigations; some family members pending or expired.
2.4 Competitive Position
The patent environment indicates significant research activity in quinoline derivatives for IBD, with competitors filing related compounds. The '743 patent's claims on specific derivatives and treatment methods give it robust territorial rights, though broader chemical scope may face narrowing due to prior art.
3. Analysis of Patent Claims and enforceability
3.1 Novelty and Inventive Step
- Novelty: The claims specify unique substitutions on the imidazoquinoline core not disclosed in prior art.
- Inventive step: Demonstrated through evidence of unexpectedly enhanced efficacy in IBD animal models, supporting inventive contribution over previous quinoline compounds.
3.2 Claim Breadth and Scope
- The compound claims are moderately narrow but cover key derivatives.
- Composition and method claims are more robust, extending protection over formulations and treatment methods.
3.3 Potential Infringement Risks
Infringement occurs if the following parameters are met:
| Criterion |
Description |
| Use of claimed derivatives |
Any compound falling within the structural scope |
| Formulation |
Use of the patented compositions in specified dosage forms |
| Method |
Practicing the claimed methods of therapy |
Competitors proposing different chemical scaffolds (e.g., pyridines) but targeting similar pathways may avoid infringement.
4. Strategic Implications
| Aspect |
Key Point |
| Patent strength |
The combination of compound, formulation, and method claims provides comprehensive protection for the innovator’s therapies targeting IBD |
| Potential challenges |
Narrowness of chemical claims; possible design-around options targeting similar pathways with distinct structures |
| Lifecycle management |
Filing continuation applications to extend patent coverage; international strategy supported by family patents |
5. Comparison with Similar Patents
| Patent |
Highlights |
Differences from '743 |
Limitations |
| US 7,987,645 |
Quinoline derivatives for autoimmune diseases |
Broader claims, less specific substituents |
Lacks detailed synthetic methods |
| WO 2010/124553 |
Quinoline compounds for IBD |
Similar therapeutic target |
Different chemical core |
The '743 patent is more specific in chemical scope compared to broader autoimmune patents, indicating a targeted approach with higher validity.
6. Frequently Asked Questions (FAQs)
Q1: What is the core chemical structure covered by the '743 patent?
Answer: The patent claims compounds based on an imidazoquinoline scaffold with specific substituents, notably halogenated and alkylated derivatives designed for immunomodulatory activity.
Q2: Does this patent cover all quinoline derivatives for IBD?
Answer: No. It covers a defined subset with particular structural features. Other quinoline-based compounds not meeting these claims are outside its scope.
Q3: Can a competitor develop similar compounds without infringing?
Answer: Yes, by designing molecules outside the scope of the patent claims, such as different scaffolds like pyridines or non-quinoline structures.
Q4: What are the key limitations in the patent claims?
Answer: They specify particular substitutions on the core, limiting claims to certain derivatives; formulations and methods are also confined to the described compositions and therapeutic protocols.
Q5: How long is the patent enforceable?
Answer: Typically, U.S. patents granted before June 8, 1995, last 17 years from issue; for patents filed after this date, enforceability extends 20 years from the earliest filing date, which in this case would be May 14, 2028.
7. Key Takeaways
- The '743 patent offers a robust yet targeted scope for specific imidazoquinoline derivatives used in IBD treatment, with well-defined chemical, formulation, and method claims.
- Its patent landscape is active, with prior art comprising similar chemical classes and therapeutic targets, but claims are sufficiently specific to provide meaningful protection.
- Strategic developments should consider the narrowness of compound claims, while exploiting broader composition and method claims for licensing or extensions.
- Legal enforceability depends on maintaining patent rights, monitoring the patent landscape for emerging filings, and exploring design-around opportunities.
- Continual innovation and patent family filings can extend market exclusivity beyond current expiry estimates.
References
[1] U.S. Patent and Trademark Office (USPTO) Official Database, Patent No. 8,101,743, granted Jan 17, 2012.
[2] Scientific Publications on Quinoline Derivatives and IBD, PubMed, 2010-2022.
[3] Patent Landscape Reports, PatentScope and EPO Espacenet, accessed 2023.
[4] WHO International Patent Classification (IPC) codes related to pharmaceuticals, 2022.
[5] Patent Law and Filing Strategies, "Managing Patent Risks in Pharmaceutical Innovation," Journal of Patent Law, 2021.
